Pages

Wednesday, May 5, 2010

Hopeful radiation therapy for patients: An alternative way of internal radiation


Conventional approaches for certain cancer patients treatment are using drugs or specialized medical instrument with therapeutical means (radiation, heat, ect.) Recently, a targeting molecule (drug) conjugated with a radionuclide offers a personalized treatment for a internal radiation therapy.The most updated status is on phase III in U.S.. An eye-catching news is not merely from scientific and clinical results but on the battleground a business real deal between Bayer and Algeta.

This is a $800M transaction and Algeta received $61M upfront payment. Algeta is a Nordic public company and shares trading at many stock exchange markets. Less than 50 employees work for this company. Even the Eurozone encountered a string of economic drawbacks, Algeta was successful on latest fund raising and appealing Big partner (pharma).

by alveice Team (alveice@gmail.com)